Stockreport

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nuvation Bio Inc. Class A  (NUVB) 
PDF U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-s [Read more]